Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Intercept's Revised NASH Trial Improves Prospects

Executive Summary

The pivotal REGENERATE study of Ocaliva now can succeed if either of two co-primary endpoints is achieved. Intercept also will use a new "objective" definition of NASH resolution in the study.


Related Content

Intercept Increases Chance Of Success In NASH Without Significant Delay
Genfit Says Safety/Tolerability Will Give Elafibranor An Edge In NASH
Endpoint Selection Could Help Determine The NASH Race
The NASH Pipeline: Replete With Targets And New Compounds
'Clean Label' For Intercept's Ocaliva In PBC Bodes Well For NASH Claim
NASH Drugs Soon May Have A Registrational Pathway, Finally
Searching For Surrogate Endpoints Requires Teamwork


Related Companies